Cotrimoxazole in hospitalised patients with severe COVID-19 infection compared to the standard of care â?? an investigator-initiated, randomised controlled trial (CoTroxCov Study)

Dept of Health and Family Welfare Government of West Bengal0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•a. Adult individuals, age >18 and <65 years
•b. COVID-19 infection documented by a positive RT-PCR test
•c. Hospitalised patients with severe COVID-19 infection, characterized by
•fever (at the time of screening or when admitted) and requiring supplemental oxygen through non- re-breath mask between 10L-15L/ min.
•d. Clinical/radiological evidence of interstitial pneumonia requiring admission (optional)
•e. Informed verbal consent under urgent conditions, documented in the electronically

•a. Patients who require invasive or non-invasive (including CPAP and high flow nasal cannula) ventilation at the time of inclusion.
•b. AST/ALT values >5 fold the ULN.
•c. Documented impairment of renal function
•d. Absolute neutrophil count below 500 cells/mm3
•e. Absolute platelet count below 50,000 cells/mm3
•f. Documented sepsis or high suspicion of superimposed severe bacterial or fungal infection
•g. Comorbidities or concomitant medications likely to be incompatible for cotrimoxazole use
•h. Pregnancy or lactation.
•i. History of cotrimoxazole hypersensitivity
•j. Patients participating in another clinical trial for SARS-CoV-2 infection

发起方

Dept of Health and Family Welfare Government of West Bengal